UroGen Pharma to Present at Ladenburg Thalmann Healthcare Conference
A live webcast of the presentation will be available on the Investors section of UroGen's website, www.urogen.com. A replay of each webcast will be available on the website for approximately 30 days.
About
UroGen is a biopharmaceutical company dedicated to building novel solutions that treat specialty cancers and urologic diseases because patients deserve better options. UroGen has developed RTGel™ reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs. UroGen’s sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option. UroGen’s first commercial product, and investigational treatment UGN-102 (mitomycin) for intravesical solution for patients with low-grade non-muscle invasive bladder cancer, are designed to ablate tumors by non-surgical means. UroGen is headquartered in
View source version on businesswire.com: https://www.businesswire.com/news/home/20210707005243/en/
INVESTOR CONTACT:
lroth@burnsmc.com
212-213-0006
MEDIA CONTACT:
Head of Communications
Eric.VanZanten@urogen.com
610-529-6219
Source: